AbbVie reported record annual revenue and adjusted EPS above guidance, offsetting $16 billion in Humira sales erosion.
AbbVie reported total net revenues of $61.2 billion for the year, exceeding its initial expectations by over $2 billion. The company attributed the growth to an 8.6% increase in sales, setting a new revenue record despite nearly $16 billion in lost U.S. Humira sales due to exclusivity loss.
Adjusted earnings per share reached $10.54, surpassing the midpoint of the company’s initial guidance. AbbVie also highlighted a 90% increase in adjusted R&D investment, funding approximately 90 clinical programs currently in development.
The company’s performance reflects stronger-than-expected revenue growth and continued pipeline expansion, reinforcing its financial momentum.